U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07229417) titled 'IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma' on Nov. 13.
Brief Summary: To learn if ivonescimab can help to control endocrine-refractory HR+ HER2- and/or TN mILC.
Study Start Date: Oct. 22
Study Type: INTERVENTIONAL
Condition:
Metastatic Endocrine Refractory
Triple Negative Invasive Lobular Carcinoma
Intervention:
DRUG: Ivonescimab
Given by IV
Recruitment Status: RECRUITING
Sponsor: M.D. Anderson Cancer Center
Published by HT Digital Content Services with permission from Health Daily Digest....